Wall Street is bullish on Viking, but the company still has a lot to prove Viking has a number of different clinical studies ongoing with its lead GLP-1 candidate, VK2735, which is a dual GLP-1 ...
Right now, Novo Nordisk and Eli Lilly are the biggest players in town when it comes to treating diabetes and obesity. Viking Therapeutics has a unique candidate in its pipeline that could disrupt ...
减肥药物赛道的竞争异常激烈，但华尔街对一家名为Viking Therapeutics（NASDAQ: VKTX）的开发阶段的制药公司寄予厚望。有分析师预测，该股将从目前的约34美元飙升至110美元，涨幅超过220%。这一目标 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback